<DOC>
	<DOCNO>NCT00212589</DOCNO>
	<brief_summary>Until recently , bolus 5-flourouracil ( FU ) + folinic acid ( FA ) consider standard chemotherapy patient colorectal cancer . Several study show Capecitabine effective Mayo regimen . The Nordic FU/FA schedule develop active tolerable bolus regimen . The Nordic regimen consist short ( 3 minute ) bolus injection FU 30 minute later FA 2 consecutive day 2 week . In randomized study efficacy comparable FU/FA regimen . It claim patient prefer oral therapy randomize study compare oral therapy ( UFT/FA ) bolus FU/FA ( Mayo ) 84 % preferred oral therapy . In present randomize cross-over study patient randomize 3 course Nordic FU/FA follow 2 course Capecitabine ( vice versa ) , patient ask preference .</brief_summary>
	<brief_title>Patients Preference Oral i.v . Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Indication treatment FUregime WHO Performance Status 01 Life expectancy &gt; 3 month Adequate haematological , renal hepatic function Adequate contraceptive Written inform consent Known CNSmetastases Prior treatment chemotherapy Pregnant breast feed woman Current infection , unresolved bowel obstruction subobstruction , uncontrolled Crohn 's disease ulcerative colitis serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>Patients preference</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Fluorouracil + folinic acid</keyword>
	<keyword>Cross-over study</keyword>
</DOC>